OTC Markets EXMKT - Delayed Quote USD
Canntab Therapeutics Limited (CTABF)
0.0001
0.0000
(0.00%)
At close: April 23 at 4:00:00 PM EDT
Breakdown
TTM
5/31/2022
5/31/2021
5/31/2020
Total Revenue
73.4760
293.3620
--
133.3340
Cost of Revenue
105.8170
223.8940
--
--
Gross Profit
-32.3410
69.4680
--
--
Operating Expense
2,564.3830
3,666.8160
3,330.7600
2,713.9970
Operating Income
-2,596.7240
-3,597.3480
-3,330.7600
-2,580.6630
Net Non Operating Interest Income Expense
-828.7150
-566.6720
-188.7220
-26.5810
Other Income Expense
69.9380
474.8340
-900.3000
--
Pretax Income
-3,355.5010
-3,689.1860
-4,419.7820
-2,607.2440
Net Income Common Stockholders
-3,355.5010
-3,689.1860
-4,419.7820
-2,607.2440
Diluted NI Available to Com Stockholders
-3,355.5010
-3,689.1860
-4,419.7820
-2,607.2440
Basic EPS
-0.09
-0.10
-0.13
-0.10
Diluted EPS
-0.09
-0.10
-0.13
-0.10
Basic Average Shares
38,889.2300
37,723.9250
34,552.6750
27,168.5630
Diluted Average Shares
38,889.2300
37,723.9250
34,552.6750
27,168.5630
Total Operating Income as Reported
-3,007.6480
-4,164.0200
-3,519.4820
-2,607.2440
Rent Expense Supplemental
30
--
--
3.1250
Total Expenses
2,670.2000
3,890.7100
3,330.7600
2,713.9970
Net Income from Continuing & Discontinued Operation
-3,355.5010
-3,689.1860
-4,419.7820
-2,607.2440
Normalized Income
-3,425.4390
-4,164.0200
-3,519.4820
-2,607.2440
Interest Income
12.3770
--
--
8.4610
Interest Expense
826.2850
566.6720
188.7220
26.5810
Net Interest Income
-828.7150
-566.6720
-188.7220
-26.5810
EBIT
-2,529.2160
-3,122.5140
-4,231.0600
-2,580.6630
EBITDA
-1,938.4100
-2,487.7970
-3,684.7180
-2,285.0470
Reconciled Cost of Revenue
105.8170
223.8940
--
--
Reconciled Depreciation
590.8060
634.7170
546.3420
295.6160
Net Income from Continuing Operation Net Minority Interest
-3,355.5010
-3,689.1860
-4,419.7820
-2,607.2440
Total Unusual Items Excluding Goodwill
69.9380
474.8340
-900.3000
--
Total Unusual Items
69.9380
474.8340
-900.3000
--
Normalized EBITDA
-2,008.3480
-2,962.6310
-2,784.4180
-2,285.0470
5/31/2020 - 11/28/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade